Form 4: OptimizeRx CFO/COO Edward Stelmakh Reports Stock Transactions

OptimizeRx CFO/COO Edward Stelmakh reported the acquisition of 5,237 shares of common stock through the vesting of restricted stock units and the disposition of 1,316 shares to cover tax obligations.

Summary

• Edward Stelmakh, the CFO/COO of OptimizeRx Corp, reported transactions involving the company's common stock.
• On December 19, 2024, Mr. Stelmakh acquired 5,237 shares of common stock through the vesting of restricted stock units.
• These restricted stock units convert into common stock on a one-for-one basis.
• Also on December 19, 2024, 1,316 shares were disposed of at a price of $4.75 per share to satisfy tax withholding obligations.
• Following these transactions, Mr. Stelmakh beneficially owns 37,287 shares of common stock and 10,474 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transactions are routine and related to executive compensation. There is no indication of positive or negative sentiment from the transactions themselves.

Positives

• The vesting of restricted stock units indicates a form of compensation and alignment of interests with the company's performance.

Negatives

• The disposition of shares to cover tax obligations, while standard, reduces the overall shareholding of the reporting person.

Risks

• The sale of shares to cover tax obligations could be perceived negatively by some investors, although it is a common practice.
• Changes in executive holdings can sometimes be a signal of internal sentiment, although this transaction appears routine.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It does not indicate any specific trend in the pharmaceutical technology industry.

Comparison to Industry Standards

• Stock-based compensation and tax-related dispositions are standard practices across publicly traded companies, including those in the technology and healthcare sectors.
• Similar transactions are regularly reported by executives at companies like Veeva Systems (VEEV) and Teladoc Health (TDOC), which are also in the healthcare technology space.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation practices.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

OptimizeRx, OPRX, Edward Stelmakh, CFO, COO, stock transaction, restricted stock units, Form 4, insider trading